Medical Use
Polivy is a CD79b-targeted antibody-drug conjugate used alongside bendamustine and rituximab to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
Recommended Dosage: Administer 1.8 mg/kg of Polivy as an intravenous infusion over 90 minutes every 21 days for 6 cycles, in combination with bendamustine and rituximab. If the initial infusion is well-tolerated, subsequent infusions may be given over 30 minutes. Premedicate with an antihistamine and antipyretic before the polatuzumab vedotin injection. If a dose is missed, administer it as soon as possible and adjust the schedule to maintain a 21-day interval between doses.
Warning & Precautions
Polatuzumab vedotin can lead to peripheral neuropathy, including severe cases, which may appear as early as the first treatment cycle and tends to accumulate over time. It can also worsen existing peripheral neuropathy. Patients should be assessed for symptoms of this condition.
Infusion-related reactions, including severe cases, can occur with polatuzumab vedotin. Administer an antihistamine and antipyretic before the infusion and monitor patients closely during the process. If a reaction occurs, stop the infusion and provide appropriate medical management.
Polivy treatment can cause serious myelosuppression, including neutropenia, anemia, and thrombocytopenia. Complete blood counts (CBC) should be monitored throughout therapy. Cytopenias may necessitate a delay, dose reduction, or interruption of therapy. Consider administering prophylactic G-CSFs.
Serious or fatal infections, including opportunistic infections like sepsis, pneumonia (including Pneumocystis jiroveci and other fungal pneumonia), cytomegalovirus, and herpesvirus infections, have been reported in patients treated with polatuzumab. Monitor patients for signs of infection during therapy and provide prophylaxis for herpesvirus and Pneumocystis jiroveci pneumonia.
Progressive multifocal leukoencephalopathy (PML) has been reported following polatuzumab treatment. Assess patients for new or worsening neurological, cognitive, or behavioral changes. If PML is suspected, halt this therapy and any concomitant chemotherapy, and permanently discontinue treatment if the diagnosis is confirmed.
Polivy may cause tumor lysis syndrome, particularly in patients with a high tumor burden and rapidly proliferating tumors. Monitor these patients and consider appropriate prophylactic measures.
Severe hepatotoxicity, consistent with hepatocellular injury and including elevated transaminases or bilirubin, has occurred in patients treated with Polivy. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin levels.
Due to its mechanism of action, polatuzumab vedotin can cause fetal harm if administered to pregnant women. Women of reproductive age should use effective contraception during treatment and for at least three months after the final dose.
Documentation Availability
Documents required to import Polivy to India?
Polivy (Polatuzumab Vedotin-piiq) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Polivy (Polatuzumab Vedotin-piiq) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for Polivy®?
The generic name for Polivy® is Polatuzumab Vedotin-piiq.
Who manufactures Polivy®?
Polivy® is manufactured by Genentech, Inc.
Is Polivy® FDA approved?
Yes, Polivy® received FDA approval on June 10, 2019.
What is diffuse large B-cell lymphoma (DLBCL)?
DLBCL is an aggressive type of lymphoma that affects B cells, which are white blood cells that help protect the body from infections. It can occur at any age but is more common in older adults, typically diagnosed between ages 65 and 74. It affects both men and women, though it is slightly more prevalent in men.
What does relapsed or refractory (R/R) mean?
Relapsed refers to the return of the disease or its symptoms after a period of improvement. Refractory means the disease has not responded to previous treatments. R/R DLBCL stands for relapsed or refractory diffuse large B-cell lymphoma.
How is Polivy administered?
Polivy is given as an intravenous (IV) infusion in a clinic or infusion center. If you experience any adverse reactions during or after the infusion, discuss them with your healthcare provider.
What are the common side effects of Polivy®?
Common side effects include low blood cell counts, nerve problems in the arms and legs, fatigue, diarrhea, nausea, decreased appetite, fever, and infections.
How much does Polivy 140 mg cost in India?
The cost of Polivy 140 mg in India can vary. For authentic procurement, you can reach out to Rx4u team.
What are the storage conditions for Polivy®?
Store Polivy® in its original carton at 2-8°C (36-46°F) to protect it from light. Do not freeze or shake it, and do not use it beyond the expiration date on the carton.
What recent updates are there for Polivy?
The FDA has recently expanded the use of Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the first-line treatment of DLBCL.
How effective is Polivy in treating DLBCL?
Clinical trials have shown that Polivy, when combined with other treatments like R-CHP, significantly improves progression-free survival and overall response rates in patients with DLBCL compared to standard therapies.
How can patients manage side effects of Polivy?
To manage side effects such as peripheral neuropathy, patients should communicate openly with their healthcare providers, adjust dosages if necessary, and consider physical therapy. For gastrointestinal symptoms, dietary changes and medications to control nausea and diarrhea may help.
Can Polivy be used for other types of lymphoma?
While Polivy is primarily approved for DLBCL, ongoing clinical trials are exploring its effectiveness in other types of B-cell lymphomas. Consult your healthcare provider to see if Polivy could be an option for your condition.
What are the long-term outcomes for patients on Polivy?
Long-term outcomes are still being studied, but initial data suggest improved survival rates and better disease management compared to standard therapies. Regular follow-up with healthcare providers is essential to monitor health and adjust treatment as needed.
Is it safe to buy Polivy online in India?
Yes, you can safely purchase Polivy online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
